Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 5/20 | 0.50 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 4/20 | 0.50 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.50 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.50 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 8/20 | 0.59 |
| ▸ | CES1 | P23141 | 8/20 | 0.59 |
| ▸ | CES2 | O00748 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | PPARD | Q03181 | 5/20 | 0.50 |
| ▸ | PPARA | Q07869 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL196410 | 1.00 | FAAH (0.59) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2573096 | 0.98 | FAAH (0.61) | FAAHCES1CES2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9458888 | 0.98 | FAAH (0.58) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL638951 | 0.98 | FAAH (0.61) | FAAHCES1CES2MEN1KMT2A | |
| Bromide SCHEMBL1244460 | 0.95 | FAAH (0.59) | FAAHCES1CES2MEN1KMT2A | |
| Water SCHEMBL3120172 | 0.95 | FAAH (0.59) | FAAHCES1CES2MEN1KMT2A | |
| Water SCHEMBL11595702 | 0.95 | FAAH (0.59) | FAAHCES1CES2MEN1KMT2A | |
| Fluoride SCHEMBL10493503 | 0.95 | FAAH (0.59) | FAAHCES1CES2MEN1KMT2A | |
| Iodide SCHEMBL8433341 | 0.95 | FAAH (0.59) | FAAHCES1CES2MEN1KMT2A | |
| Bromide SCHEMBL6552300 | 0.95 | FAAH (0.59) | FAAHCES1CES2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025074340-A1 | A PROCESS FOR PREPARATION OF AMINOBIPHENYL COMPOUNDS AND INTERMEDIATES THEREOF | UPL LIMITED (IN) | 2025-04-10 | — | — | WO | claimed |
| WO-2024189550-A1 | PROCESS FOR THE PREPARATION OF ISAVUCONAZONIUM SULFATE AND ITS CRYSTALLINE FORMS | APITORIA PHARMA PRIVATE LIMITED (IN) | 2024-09-19 | — | — | WO | claimed |
| US-20240057934-A1 | WEARABLE DEVICE FOR DETECTION OF AMNIOTIC FLUID | SAVYON DIAGNOSTICS LTD (IL) | 2024-02-22 | — | — | US | claimed |
| EP-4277584-A1 | WEARABLE DEVICE FOR DETECTION OF AMNIOTIC FLUID | Peptonic Medical Israel Ltd (IL) | 2023-11-22 | — | — | EP | claimed |
| WO-2022153291-A1 | WEARABLE DEVICE FOR DETECTION OF AMNIOTIC FLUID | PEPTONIC MEDICAL ISRAEL LTD (IL) | 2022-07-21 | — | — | WO | claimed |
| US-11135338-B2 | Diagnostic composition for identifying amniotic fluid | COMMON SENSE LTD. (US) | 2021-10-05 | — | — | US | claimed |
| US-20190240373-A1 | DIAGNOSTIC COMPOSITION FOR IDENTIFYING AMNIOTIC FLUID | COMMON SENSE LTD. | 2019-08-08 | — | — | US | claimed |
| US-10265692-B2 | Ex vivo methods for predicting and confirming in vivo metabolism of pharmaceutically active compounds | EMPIRIKO CORPORATION (US) | 2019-04-23 | — | — | US | claimed |
| US-9981898-B1 | Process for oxidation of fatty alkenols to alkenal pheromone products | PROVIVI, INC. (US) | 2018-05-29 | — | — | US | claimed |
| US-20160303553-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EMPIRIKO CORPORATION | 2016-10-20 | — | — | US | claimed |
| US-4626288-A | Starch derivatives forming reversible gels | NATIONAL STARCH AND CHEMICAL CORPORATION (US) | 1986-12-02 | — | — | US | claimed |
| EP-0188237-A1 | Reversible gels of starch derivatives | National Starch and Chemical Corporation (US) | 1986-07-23 | — | — | EP | claimed |
| US-4539422-A | Process for preparing cephalosporin intermediates | ELI LILLY AND COMPANY (US) | 1985-09-03 | — | — | US | claimed |
| EP-0136145-A2 | Process for preparing alkyl cyanoformates | ELI LILLY AND COMPANY (US) | 1985-04-03 | — | — | EP | claimed |
| US-4422970-A | ALKYLATION OF AZACYCLOHEPTAN-2-ONE, QUATERNARY AMMONIUM PHASE TRANSFER CATALYST | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1983-12-27 | — | — | US | claimed |
| EP-0095096-A2 | Improved method of synthesis of 1-substituted azacycloalkan-2-ones | Whitby Research Incorporated (US) | 1983-11-30 | — | — | EP | claimed |
| US-4359429-A | Mercaptoacetonitrile synthesis | W. R. GRACE & CO. (US) | 1982-11-16 | — | — | US | claimed |
| US-4304929-A | Process for preparing 4-(n-hexadecylamino)-benzoic acid | LEK TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV, N.SOL.O. (YU) | 1981-12-08 | — | — | US | claimed |
| US-4225428-A | USING QUATERNARY AMMONIUM CHLORIDE AND PERCHLORIC ACID | PETROVICH VOJISLAV | 1980-09-30 | — | — | US | claimed |
| US-3992432-A | Phase transfer catalysis of heterogeneous reactions by quaternary salts | CONTINENTAL OIL COMPANY (US) | 1976-11-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303553-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | CYP3A43, CYP3A4, CYP2D6 | PPARG 769/4885HDAC11 778/4885ESR1 2251/4885 |
| US-10265692-B2 | Ex vivo methods for predicting and confirming in vivo metabolism of pharmaceutically active compounds | CYP3A43, CYP3A4, CYP2D6 | PPARG 769/4885HDAC11 778/4885ESR1 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.